Cheminformatics Approaches to Fragment-based Lead Discovery

Fragment-based Approaches in Drug Discovery

Volumn 34, Issue , 2006, Pages 89-111

  Oprea, Tudor I ^a   Blaney, Jeffrey M ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b SGX Pharmaceuticals Inc   (United States)

Author keywords

Chemical space of small molecules (under 300 a.m.u.); Computional approaches; Concept of lead likeness; Drug discovery; Fragment library design; Fragment based lead discovery; Literature based identification of fragments

Indexed keywords

COMPUTIONAL APPROACHES; CONCEPT OF LEAD-LIKENESS; DRUG DISCOVERY; FRAGMENT-BASED LEAD DISCOVERY; LIBRARY DESIGNS; LITERATURE-BASED IDENTIFICATION OF FRAGMENTS; SMALL MOLECULES;

MOLECULES;

EID: 84891324508     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608761.ch5     Document Type: Chapter

References (58)

1. Kubinyi, H. 1999, Chance favors the prepared mind - from serendipity to rational drug design. J. Rec. Signal Transduction Res. 19, 15-39.
2. Bell, A. S., Terrett, N. K., Brown, D. 1992, Pyrazolopyrimidinone antianginal agents. EU Patent EP0463756, available at: http://12.espacenet.com/espacenet/viewer?PN=EP0463756.
3. Ellis, P., Terrett, N. K. 1994, Pyrazolopyrimidininones for the treatment of impotence. EU Patent EP0702555, available at: http://12.espacenet.com/espacenet/viewer?PN=WO9428902.
4. Terrett, N. K., Bell, A. S., Brown, D., Ellis, P. 1996, Sildenafil (VIAGRA?), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction, Bioorg. Med. Chem. Lett. 6, 1819-1824.
5. Ondetti, M. A., Cushman, D. W. 1976, Compounds and method for alleviating angiotensin related hypertension. US Patent 4,053,651.
6. Von Unge, S. 1995, Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles. EU Patent WO9532957, available at: http://12.espacenet.com/espacenet/viewer?PN=WO9532957.
7. Drews, J. 1998, Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D. Drug Discov. Today, 3, 491-494.
8. Horrobin, D. F. J. Royal Soc. Med. 2000, Innovation in the pharmaceutical industry. 93, 341-345.
9. DeStevens, G. 1986, Serendipity and structured research in drug discovery. Prog. Drug. Res. 30, 189-203.
10. Sneader, W. 1996, Drug Prototypes and their Exploitation, Wiley, Chichester.
11. Hann, M. M., Oprea, T. I. 2004, Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8, 255-263.
12. Fattori, D. 2004, Molecular recognition: the fragment approach in lead generation. Drug Discov. Today 9, 229-238.
13. Kappler, M. A., Allu, T. K., Bologa, C., Oprea, T. I. 2005, Exhaustive Enumeration of Small Molecules. 1. Simple Graphs. J. Chem. Inf. Model. (in preparation).
14. Screensaver Lifesaver 2005, available at: http://www.chem.ox.ac.uk/curecancer.html.
15. Weininger, D. 1988, SMILES 1. Introduction and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31-36.
16. Weininger, D., Weininger, A., Weininger, J. L. 1989, SMILES 2. Algorithm for generation of unique SMILES notation. J. Chem. Inf. Comput. Sci. 29, 97-101.
17. World Drug Index database 2005, Der-went Publications, available at: http://www.derwent.com/products/lr/wdi/; and Daylight Chemical Information Systems, available at: http://www.daylight.com/products/databases/WDI.html.
18. Hann, M. M., Leach, A., Green, D. V. S. 2005, Computational chemistry, molecular complexity and screening set design. In: Cheminformatics in Drug Discovery. ed. Oprea, T. I., Wiley-VCH, New York, p. 43-57.
19. Oprea, T. I. 2004, Cheminformatics in Lead Discovery. In: Cheminformatics in Drug Discovery. ed. Oprea, T. I., Wiley-VCH, New York, p. 23-41.
20. Bindra, J. S., Lednicer D. (eds.) 1982, Chronicles of Drug Discovery, Vol. 1, Wiley-Interscience, New York.
21. Bindra, J. S., Lednicer D. (eds.) 1983, Chronicles of Drug Discovery, Vol. 2, Wiley-Interscience, New York.
22. Lednicer, D. (ed.) 1993, Chronicles of Drug Discovery, Vol. 3, ACS Publishers, Washington D.C.
23. Sneader, W. 1996, Drug Prototypes and their Exploitation, Wiley, Chichester.
24. Borchardt, R. T., Freidinger, R. M., Sawyer, T. K., Smith P. L. (eds.) 1998, Integration of Pharmaceutical Discovery and Development: Case Histories, Plenum Press, New York.
25. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25.
26. Leo, A., Weininger, D. 2005, ClogP ver. 4.0, Daylight Chemical Information Systems, Santa Fe, available at: http://www.daylight.com/.
27. Ajay, Walters, W. P., Murcko, M. A. 1998, Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J. Med. Chem. 41, 3314-3324.
28. Sadowski, J., Kubinyi, H. 1998, A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 41, 3325-3329.
29. MDDR and ACD 2005, MDL Information Systems, available at: http://www.mdli.-com/products/finders/database_finder/; MDDR is developed in cooperation with Prous Science Publishers, available at: http://www.prous.com/index.html.
30. Wagener, M., Van Geerenstein, V. J. 2000, Potential drugs and nondrugs: prediction and identification of important structural features. J. Chem. Inf. Comput. Sci. 40, 280-292.
31. Frimurer, T. M., Bywater, R., Naerum, L., Lauritsen, L. N., Brunak, S. 2000, Im-proving the odds in discriminating "drug-like" from "nondruglike" compounds. J. Chem. Inf. Comput. Sci. 40, 1315-1324.
32. Brüstle, M., Beck, B., Schindler, T., King, W., Mitchell, T., Clark, T. 2002, Descriptors, physical properties and drug-likeness. J. Med. Chem. 45, 3345-3355.
33. Oprea, T. I. 2000, Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Design 14, 251-264.
34. Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., Hipskind, P. A. 2004, Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232.
35. Teague, S. J., Davis, A. M., Leeson, P. D., Oprea, T. I. 1999, The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 38, 3743-3748 (in German: Angew. Chem. 1999, 111, 3962-3967).
36. Hann, M. M., Leach, A. R., Harper, G. 2001, Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864.
37. Oprea, T. I., Davis, A. M., Teague, S. J., Leeson, P. D. 2001, Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41,1308-1315.
38. Proudfoot, J. R. 2002, Drugs, leads, and drug-likeness: An analysis of some recently launched drugs, Bioorg. Med. Chem. Lett. 12, 1647-1650.
39. Davis, A. M., Teague, S. J., Kleywegt, G. J. 2003, Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 42, 2718-2736 (in German: Angew. Chem. 2003, 115, 2822-2841).
40. Goodnow Jr., R. A., Gillespie, P., Bleicher, K. 2005, Chemoinformatic tools for library design and the hit-to-lead process: A user's perspective. In: Cheminformatics in Drug Discovery. Oprea, T. I. (ed.), Wiley-VCH, New York, p. 381-435.
41. Sanders, W. J., Nienaber, V. L, Lerner, C. G., McCall, J. O., Merrick, S. M., Swanson, S. J., Harlan, J. E., Stoll, V. S., Stamper, G. F., Betz, S. F., Condroski, K. R., Meadows, R. P. Severin, J. M., Walter, K. A., Magdalinos, P., Jakob, C. G., Wagner, R., Beutel, B. A. 2004, Discovery of Potent Inhibitors of Dihydroneopterin Aldolase Using CrystaLEAD High-Throughput X-ray Crystallographic Screening and Structure-Directed Lead Optimization. J. Med. Chem. 47, 1709-1718.
42. Kenakin, T. 2003, Predicting therapeutic value in the lead optimization phase of drug discovery. Nat. Rev. Drug Discov. 2, 429-438.
43. Tetko, I. V., Tanchuk, V. Y. 2002, Application of associative neural networks for prediction of lipophilicity in AlogPS 2.1 program. J. Chem. Inf. Comput. Sci. 42, 1136-1145.
44. Vandenberg, J. I., Walker, B. D., Campbell, T.J. 2001, HERG K+ channels: friend or foe. Trends Pharm. Sci. 22, 240-246.
45. Carr, R., Jhoti, H. 2002, Structure-based screening of low-affinity compounds. Drug Discov. Today 7, 522-527.
46. Hartshorn, M. J., Murray, C. W., Cleasby, A., Frederickson, M., Tickle, I. J., Jhoti, H. 2005, Fragment-Based Lead Discovery Using X-ray Crystallography. J. Med. Chem. 48, 403-413.
47. Milburn, M. V. 2002, Drug discovery on a proteomic scale. Abstr. Pap. ACS Nat. Meet. 224, COMP-042.
48. Moore, J., Abdlu-Manan, N., Fejzo, J., Jacobs, M., Lepre, C., Peng, J., Xie, X. 2004, Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design. J. Synchrotron Radiation 11, 97-100.
49. Blaney et al. 2005, Chapter 11 in this book
50. Congreve, M., Carr, R., Murray, C., Jhoti, H. 2003, A"Rule of Three" for fragment-based lead discovery? Drug Discov. Today 8, 876-877.
51. Olah, M., Mracec, M., Ostopovici, L., Rad, R., Bora, A., Hadaruga, N., Olah, I., Banda, M., Simon, Z., Mracec, M., Oprea, T. I. 2005, WOMBAT: World of Molecular Bioactivity. In: Chemoinformatics in Drug Discovery. ed. Oprea, T. I., Wiley-VCH, New York, p. 223-239.
52. Olah, M., Oprea, T. I. 2006, Informatics and databases: Bioactivity databases. In: Comprehensive Medicinal Chemistry II, Vol. 3, ed. Taylor, J., Triggle, D., Elsevier, New York (in press).
53. WOMBAT 2005, Sunset Molecular Discovery, Santa Fe, available at: http://www.sunsetmolecular.com/.
54. Andrews, P. R., Craik, D. J., Martin, J. L. 1984, Functional group contributions to drug-receptor interactions. J. Med. Chem. 27, 1648-1657.
55. Kuntz, I. D., Chen, K., Sharp, K. A., Kollman, P. A. 1999, The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 96, 9997-10002.
56. ExPASy 2005, Enzyme Nomenclature Database, available at: http://www.expasy.org/enzyme/.
57. ChemoSoft 2005, available at: http://www.chemosoft.com/.
58. Oprea, T. I., Matter, H. 2004, Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 8, 349-358.